INTRODUCTION
The exact mechanism by which synthetic progestagens exert antifertility effects is not clear. One of their major actions is considered to be inhibition of lutein¬ izing hormone (lh) release from the pituitary gland (Pincus, 1965) . However, there is a paucity of data on the effects of these steroids on pituitary lh level. Labhsetwar (1966a) found a significant decrease in pituitary lh stores of intact female rats treated with medroxyprogesterone acetate. Others have used ovariectomized rats and/or assays which do not discriminate between follicle stimulating hormone (fsh) and lh (Saunders, 1964; Husain 8c Pincus, 1965) . It is necessary to use specific assays since non-specific assays, although informa¬ tive, sometimes lead to erroneous conclusions due to interaction between lh and fsh (Parlow, 1964) . In the present study norethynodrel ( 17a-ethynyl17a-hydroxy-A5[10]-estren-3-one) and mestranol ( 17a-ethynyl-3-methoxy-A1,3,5[10]-estratriene-17/}-ol), progestagenic and oestrogenic components, respectively, of the commercially marketed contraceptive preparation, Enovid R, have been used. They were administered to rats in dosages considered on a weight basis to fall in a range employed for fertility control in the human. The effect of these steroids on the output of gonadotrophins from the pituitary gland when administered singly or in combination was also studied. Preliminary data have appeared elsewhere (Labhsetwar, 1966b The ovarian ascorbic acid depletion method of Parlow (1958) was used. The details of the assay have been described previously (Labhsetwar, 1966a (Table 2) .
Mestranol, but not norethynodrel, caused a significant inhibition of ovarian hypertrophy together with a decrease in the number of corpora lutea ( Table 2) . The combined treatment did not result in a significantly more severe inhibition of ovarian hypertrophy than that caused by mestranol alone. The number of corpora lutea in the residual ovary paralleled the inhibition of compensatory hypertrophy.
DISCUSSION
The daily dose of norethynodrel (about 0-1 mg/kg) used in this study has been previously shown to be inadequate to block ovulation, fertility and nidation in the adult rat upon subcutaneous administration (Saunders, 1964; Desaulles & Krähenbuhl, 1964) . The uterotrophic effect of this dose of norethynodrel was also negligible (Table 1 ) and it was found ineffective in altering the ovarian sensitivity to gonadotrophins (Saunders & Drill, 1958; Eckstein & Mandl, 1962) . Thus, although this dose has been found incapable of exerting a signifi¬ cant peripheral action, the present study suggests that it is effective in increasing hypophysial lh stores. The mechanism by which norethynodrel enhances pituitary lh stores is speculative. The effect appears to be reminiscent of increase in the pituitary lh level in response to administration of natural progestagen-progesterone (Hoffman 8c Schwartz, 1965; Van Rees & de Groot, 1965) . This increase could result from an inhibition of lh release, a stimulation of lh synthesis, or both. The failure of this dose of norethynodrel to block formation of corpora lutea in the adult (Saunders, 1964) , immature (Shipley & Meyer, 1965) or post-pubertal rat (Table 2) (Schwartz & Rothchild, 1964; Van Rees & de Groot, 1965) and norethynodrel has been found capable of inducing pseudo¬ pregnancy in the cyclic rat (Labhsetwar, 1966c) . The lh level in the norethynodrel-treated group (3-7 µg/mg) is comparable to that found on Days 7 to 8 of pseudopregnancy (3-3 µg/mg; Labhsetwar, 1967) .
In contrast with the effects of norethynodrel, mestranol exerted no significant effects on hypophysial lh stores, but caused a significant ovarian atrophy (Table 1 ) and reduction in both the number of corpora lutea and the degree of ovarian hypertrophy in the post-pubertal rats ( (Paulsen, Leach, Lanman, Goldston, Maddock & Heller, 1962; Bialy, Layne & Pincus, 1965) . This conversion may further reinforce the pituitary inhibition caused by mestranol. A significant ovarian atrophy (Table 1 ) and an inhibition of compensatory hypertrophy (Table 2) in both mestranol and mestranol-norethynodrel-treated groups, but not in the norethynodrel-treated group, suggests that mestranol may have decreased fsh output in addition to that of lh.
